MetaCap

GRI Bio (GRI) vs Lakewood-Amedex Biotherapeutics (LABT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GRI Bio is the larger company by market cap ($2.4 million vs $2.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRI-39.46%LABT-71.18%
+6%-38%-82%
Oct 7, 20261 yearNov 20, 2026
GRI-35.63%LABT-68.69%
+12%-33%-79%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRI versus LABT key metrics
MetricGRILABT
Share price$1.12$0.2449
Market cap$2.45M$2.19M
1-day change0.00%+15.03%
P/E ratio (TTM)0.05—
EPS (TTM)$20.57$-5.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-11.96M—
52-week high$64.12$98.20
52-week low$1.09$0.17
Distance from 52-week high-98.25%-99.75%
Analyst consensusnonestrong_buy
Avg. price target upside+1551.79%+4799.96%
Average volume218.31K16.14M
Shares outstanding2.19M8.95M
Employees35
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About GRI Bio

GRI stock →

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About Lakewood-Amedex Biotherapeutics

LABT stock →

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

GRI vs LABT FAQ

Which is bigger, GRI Bio or Lakewood-Amedex Biotherapeutics?

GRI Bio (GRI) is larger, with a market capitalization of $2.45M compared with $2.19M for Lakewood-Amedex Biotherapeutics (LABT).

Are GRI Bio and Lakewood-Amedex Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons